argenx

argenx is a biotechnology company that develops and commercializes antibody-based therapies for autoimmune diseases. Its operating model combines antibody discovery, clinical development, regulatory activities, manufacturing partnerships, and global commercialization. Its core product, VYVGART, targets the neonatal Fc receptor (FcRn) to reduce circulating immunoglobulin G antibodies associated with autoimmune conditions. The company serves patients and healthcare providers across neurology, hematology, and other immunology markets. Its clinical pipeline includes treatments for generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, and additional antibody-mediated disorders. Its strategic focus centers on expanding FcRn-based therapies and developing new antibody technologies.